{"id":"copolymer-1","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2108999","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Copolymer 1 is a type of immunomodulatory therapy that has been shown to be effective in reducing the frequency of exacerbations in patients with multiple sclerosis. It works by inducing an immune response against the myelin basic protein, which is a key component of the myelin sheath that surrounds nerve fibers in the central nervous system. This immune response helps to reduce inflammation and damage to the myelin sheath, thereby slowing the progression of the disease.","oneSentence":"Copolymer 1 is a synthetic polymer that works by inducing an immune response against the myelin basic protein, thereby reducing inflammation in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:39.277Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT03327922","phase":"NA","title":"Interrupted Subdermal Suture Spacing During Linear Wound Closures and the Effect on Wound Cosmesis","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2017-09-20","conditions":"Interrupted Subdermal Suture","enrollment":50},{"nctId":"NCT05344469","phase":"","title":"A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Relapsing Multiple Sclerosis","enrollment":800},{"nctId":"NCT04788615","phase":"PHASE3","title":"Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-23","conditions":"Multiple Sclerosis","enrollment":185},{"nctId":"NCT04821596","phase":"NA","title":"Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2020-07-13","conditions":"Multiple Sclerosis","enrollment":77},{"nctId":"NCT05162638","phase":"NA","title":"Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pennsylvania","startDate":"2022-04-19","conditions":"Multiple Sclerosis, Healthy","enrollment":24},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT05688436","phase":"","title":"A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies","status":"RECRUITING","sponsor":"Biogen","startDate":"2021-09-24","conditions":"Multiple Sclerosis","enrollment":1178},{"nctId":"NCT05767736","phase":"","title":"A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2024-06-08","conditions":"Multiple Sclerosis","enrollment":10500},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT07189325","phase":"PHASE3","title":"A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy","enrollment":250},{"nctId":"NCT05962177","phase":"NA","title":"Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2023-09-11","conditions":"Multiple Sclerosis","enrollment":400},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT06715605","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","status":"WITHDRAWN","sponsor":"University Hospital, Antwerp","startDate":"2025-04-30","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT05710718","phase":"NA","title":"PureWick™ France and U.S. At-Home Pilot Study","status":"COMPLETED","sponsor":"C. R. Bard","startDate":"2023-10-31","conditions":"Nocturnal Enuresis","enrollment":17},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT04878211","phase":"PHASE4","title":"A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-10","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":24},{"nctId":"NCT03193866","phase":"","title":"COMparison Between All immunoTherapies for Multiple Sclerosis.","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2017-06-02","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":3526},{"nctId":"NCT06402279","phase":"","title":"Hemoperfusion Efferon СT for the Extremely Severe Form of COVID-19","status":"COMPLETED","sponsor":"Efferon JSC","startDate":"2020-10-01","conditions":"COVID-19","enrollment":130},{"nctId":"NCT06009458","phase":"NA","title":"Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acuity Polymers, Inc.","startDate":"2023-10-01","conditions":"Myopia","enrollment":387},{"nctId":"NCT06663189","phase":"PHASE3","title":"Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-01","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":200},{"nctId":"NCT03362294","phase":"PHASE2","title":"Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mapi Pharma Ltd.","startDate":"2017-12-11","conditions":"Primary Progressive Multiple Sclerosis","enrollment":30},{"nctId":"NCT02212886","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS","status":"COMPLETED","sponsor":"Mapi Pharma Ltd.","startDate":"2014-10","conditions":"Multiple Sclerosis","enrollment":25},{"nctId":"NCT05811949","phase":"","title":"Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.","status":"COMPLETED","sponsor":"IRCCS Centro Neurolesi Bonino Pulejo","startDate":"2021-02-24","conditions":"Multiple Sclerosis","enrollment":52},{"nctId":"NCT05718947","phase":"","title":"Ultra-high-field Brain MRI in Multiple Sclerosis","status":"COMPLETED","sponsor":"Zuyderland Medisch Centrum","startDate":"2023-09-12","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT03209479","phase":"","title":"Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) \"Prevention of Relapse of Multiple Sclerosis\"","status":"COMPLETED","sponsor":"Teva Takeda Pharma Ltd.","startDate":"2015-11-24","conditions":"Multiple Sclerosis","enrollment":1332},{"nctId":"NCT04472975","phase":"","title":"Prescription Drug Safety and Effectiveness in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"1996-01-01","conditions":"Multiple Sclerosis","enrollment":35000},{"nctId":"NCT06178367","phase":"PHASE3","title":"Effectiveness and Safety of Topical Hyaluronic Acid of Different Molecular Weights in Xerotic Skin Treatment","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2023-08-26","conditions":"Xerosis Cutis","enrollment":36},{"nctId":"NCT04561739","phase":"NA","title":"Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital","startDate":"2021-02-01","conditions":"De Novo Stenosis, Coronary Artery Disease","enrollment":2272},{"nctId":"NCT03399981","phase":"","title":"Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-06-01","conditions":"Progressive Multifocal Leukoencephalopathy","enrollment":80327},{"nctId":"NCT02762266","phase":"PHASE3","title":"Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization","status":"TERMINATED","sponsor":"Stanford University","startDate":"2016-02-27","conditions":"Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma","enrollment":13},{"nctId":"NCT04448977","phase":"","title":"Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2021-05-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":60},{"nctId":"NCT03409185","phase":"NA","title":"The Incidence of Glistenings in the 2017 Intraocular Lenses Made by Alcon and Abbott Medical Optics","status":"TERMINATED","sponsor":"University of Toronto","startDate":"2017-07-11","conditions":"Cataracts, Visual Acuity Reduced Transiently, Loss of Visual Contrast Sensitivity","enrollment":22},{"nctId":"NCT04121221","phase":"PHASE3","title":"A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS","status":"COMPLETED","sponsor":"Mapi Pharma Ltd.","startDate":"2019-09-19","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1016},{"nctId":"NCT06030297","phase":"NA","title":"Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.","status":"UNKNOWN","sponsor":"University of Utah","startDate":"2022-11-01","conditions":"Peripheral Neuropathy","enrollment":301},{"nctId":"NCT00988988","phase":"PHASE4","title":"The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2010-02","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT06003972","phase":"PHASE2","title":"Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2021-01-04","conditions":"Acute Decompensated Heart Failure, Cytokine Storm, Inflammatory Response","enrollment":14},{"nctId":"NCT04079088","phase":"PHASE2","title":"Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2021-06-30","conditions":"Relapsing Multiple Sclerosis","enrollment":""},{"nctId":"NCT03982212","phase":"PHASE1","title":"A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors","status":"UNKNOWN","sponsor":"University of Kansas Medical Center","startDate":"2019-07-26","conditions":"Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Basal Cell Carcinoma","enrollment":10},{"nctId":"NCT04574843","phase":"NA","title":"Middle Meningeal Artery Embolization With Liquid Embolic Agent for Treatment of Chronic Subdural Hematoma","status":"UNKNOWN","sponsor":"Mashhad University of Medical Sciences","startDate":"2020-08-01","conditions":"Chronic Subdural Hematoma","enrollment":100},{"nctId":"NCT04922593","phase":"PHASE1","title":"Relative Bioavailability of LY03010 Compared to Listed Drug","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2021-01-13","conditions":"Schizophrenia, Psychotic Disorders, Mood Disorders","enrollment":281},{"nctId":"NCT05762003","phase":"","title":"Czech Pharmaco-epidemiological Study on Disease Modifying Drugs","status":"COMPLETED","sponsor":"IMPULS Endowment Fund","startDate":"2019-01-01","conditions":"Multiple Sclerosis","enrollment":17478},{"nctId":"NCT04371549","phase":"NA","title":"Skin Closures at Cesarean Delivery, Glue vs Subcuticular Sutures.","status":"COMPLETED","sponsor":"Ain Shams Maternity Hospital","startDate":"2020-08-25","conditions":"Cesarean Wound; Dehiscence","enrollment":79},{"nctId":"NCT05528666","phase":"","title":"Risk Perception in Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-09","conditions":"Multiple Sclerosis","enrollment":4361},{"nctId":"NCT05576779","phase":"","title":"Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-03","conditions":"Multiple Sclerosis","enrollment":2101},{"nctId":"NCT01490502","phase":"PHASE3","title":"Vitamin D Supplementation in Multiple Sclerosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":172},{"nctId":"NCT00326625","phase":"PHASE2","title":"Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Teva Pharmaceutical Industries, Ltd.","startDate":"2006-07-27","conditions":"Amyotrophic Lateral Sclerosis","enrollment":366},{"nctId":"NCT01994018","phase":"","title":"Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake","status":"COMPLETED","sponsor":"OSF Healthcare System","startDate":"2011-11","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT02307877","phase":"","title":"Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-09","conditions":"Multiple Sclerosis","enrollment":157},{"nctId":"NCT00620035","phase":"PHASE3","title":"A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-03","conditions":"Contraception","enrollment":301},{"nctId":"NCT01067521","phase":"PHASE3","title":"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-06-22","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":1404},{"nctId":"NCT02499900","phase":"PHASE4","title":"Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-08-10","conditions":"Multiple Sclerosis","enrollment":861},{"nctId":"NCT00176592","phase":"PHASE4","title":"Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2003-01","conditions":"Multiple Sclerosis","enrollment":75},{"nctId":"NCT05104398","phase":"","title":"Hemoperfusion With the Efferon CT Extracorporeal Adsorbers in Patients With Severe Covid-19","status":"COMPLETED","sponsor":"Efferon JSC","startDate":"2020-10-01","conditions":"COVID-19","enrollment":42},{"nctId":"NCT02753088","phase":"PHASE3","title":"Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":158},{"nctId":"NCT03134209","phase":"NA","title":"A Study Investigating the Efficacy of Various Wound Closure Devices in Reducing Postoperative Wound Complications","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-04-26","conditions":"Joint Disease, Arthropathy","enrollment":160},{"nctId":"NCT00525668","phase":"PHASE1, PHASE2","title":"Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-09","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":120},{"nctId":"NCT04928313","phase":"","title":"Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2015-04-12","conditions":"Relapsing Multiple Sclerosis","enrollment":368},{"nctId":"NCT04846361","phase":"NA","title":"Vaginal Hygiene Wash as Adjunct Treatment in Bacterial Vaginosis","status":"UNKNOWN","sponsor":"Universiti Kebangsaan Malaysia Medical Centre","startDate":"2021-05","conditions":"Bacterial Vaginoses","enrollment":56},{"nctId":"NCT00937157","phase":"NA","title":"Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2007-09","conditions":"Multiple Sclerosis","enrollment":12},{"nctId":"NCT04727385","phase":"NA","title":"Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc Disease","status":"UNKNOWN","sponsor":"Gelmetix","startDate":"2020-09-15","conditions":"Degenerative Disc Disease, Chronic Lower Back Pain, Discogenic Pain","enrollment":20},{"nctId":"NCT01623596","phase":"PHASE4","title":"Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06-08","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":881},{"nctId":"NCT03308994","phase":"","title":"Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2017-11-01","conditions":"C10.114.375.500","enrollment":650},{"nctId":"NCT04260711","phase":"NA","title":"Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-07-01","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive","enrollment":130},{"nctId":"NCT00273364","phase":"PHASE2","title":"Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-11-16","conditions":"Multiple Sclerosis","enrollment":110},{"nctId":"NCT00203021","phase":"PHASE4","title":"Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"1994-03-26","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":208},{"nctId":"NCT02743637","phase":"PHASE1","title":"A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors","status":"COMPLETED","sponsor":"SynDevRx, Inc.","startDate":"2016-02","conditions":"Advanced Malignancy, Advanced Solid Tumors, Neoplasm","enrollment":32},{"nctId":"NCT02869360","phase":"","title":"Correlation Between PET and Advanced MRI in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2016-10","conditions":"Multiple Sclerosis","enrollment":14},{"nctId":"NCT02749396","phase":"","title":"EPID Multiple Sclerosis Pregnancy Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-02","conditions":"Multiple Sclerosis","enrollment":2089},{"nctId":"NCT02294786","phase":"PHASE2","title":"Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12-17","conditions":"Cancer","enrollment":62},{"nctId":"NCT01633112","phase":"PHASE3","title":"MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08-09","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":1064},{"nctId":"NCT03315923","phase":"PHASE2, PHASE3","title":"Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2017-12-01","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":84},{"nctId":"NCT01509950","phase":"NA","title":"Comparison of Staples Versus Prolene Suture for Skin Closure at Cesarean Delivery","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-01","conditions":"Pregnancy, Cesarean Section","enrollment":15},{"nctId":"NCT02930161","phase":"PHASE2","title":"Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome","status":"TERMINATED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2016-05-30","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":35},{"nctId":"NCT01498887","phase":"PHASE4","title":"Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-12-24","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":347},{"nctId":"NCT02153723","phase":"PHASE2","title":"Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2013-08","conditions":"Rett Syndrome","enrollment":10},{"nctId":"NCT00939549","phase":"PHASE2","title":"High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2010-11","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT03548272","phase":"PHASE4","title":"BiOSS LIM C vs 2nd Generation DES in Non-LM Bifurcations","status":"UNKNOWN","sponsor":"Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland","startDate":"2018-06-12","conditions":"Coronary Artery Disease","enrollment":518},{"nctId":"NCT02699684","phase":"NA","title":"Comparison of Lotrafilcon B Lenses With Different Packaging Solutions","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-05-12","conditions":"Refractive Error","enrollment":82},{"nctId":"NCT00078338","phase":"PHASE4","title":"Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2004-02-16","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":764},{"nctId":"NCT01569451","phase":"PHASE2","title":"Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-02","conditions":"Multiple Sclerosis","enrollment":53},{"nctId":"NCT01834586","phase":"PHASE4","title":"Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications","status":"COMPLETED","sponsor":"Brown, Theodore R., M.D., MPH","startDate":"2013-03","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT00856635","phase":"PHASE3","title":"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-02","conditions":"Optic Neuritis","enrollment":44},{"nctId":"NCT02776072","phase":"","title":"Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-05","conditions":"Multiple Sclerosis","enrollment":2978},{"nctId":"NCT01156311","phase":"PHASE2","title":"BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-06","conditions":"Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis","enrollment":108},{"nctId":"NCT01965262","phase":"NA","title":"A Clinical Assessment of the Hemacopolymer Daily Disposable Limbal Ring Soft Contact Lens","status":"COMPLETED","sponsor":"CooperVision, Inc.","startDate":"2014-04","conditions":"Myopia","enrollment":30},{"nctId":"NCT00947752","phase":"PHASE3","title":"Safety of New Formulation of Glatiramer Acetate","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-07","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":147},{"nctId":"NCT00239993","phase":"PHASE4","title":"A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2005-08","conditions":"Multiple Sclerosis","enrollment":50},{"nctId":"NCT01710228","phase":"PHASE2","title":"Alternative Treatment Paradigm for Natalizumab Trial","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-07","conditions":"Multiple Sclerosis (MS)","enrollment":""},{"nctId":"NCT01489254","phase":"PHASE3","title":"Efficacy and Safety of GTR in Comparison to Copaxone®","status":"COMPLETED","sponsor":"Synthon BV","startDate":"2011-10","conditions":"Multiple Sclerosis","enrollment":794},{"nctId":"NCT02308670","phase":"","title":"Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2014-07","conditions":"Multiple Sclerosis","enrollment":150},{"nctId":"NCT00039988","phase":"NA","title":"Treatment of Multiple Sclerosis With Copaxone and Albuterol","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-11","conditions":"Autoimmune Diseases, Multiple Sclerosis","enrollment":40},{"nctId":"NCT01903291","phase":"","title":"Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-08","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":333},{"nctId":"NCT00451204","phase":"PHASE2","title":"A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2007-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":158},{"nctId":"NCT01963611","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2013-10","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":255},{"nctId":"NCT01993004","phase":"","title":"Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2013-07","conditions":"Multiple Sclerosis","enrollment":24},{"nctId":"NCT02194621","phase":"PHASE4","title":"Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria","status":"COMPLETED","sponsor":"Colgate Palmolive","startDate":"2014-01","conditions":"Oral Bacteria Levels in the Mouth","enrollment":128},{"nctId":"NCT02323269","phase":"","title":"Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)","status":"TERMINATED","sponsor":"Biogen","startDate":"2015-05","conditions":"Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis","enrollment":24},{"nctId":"NCT02366689","phase":"PHASE4","title":"Clinical Study Comparing Dental Plaque and Gingivitis Reduction After Using One of Three Oral Hygiene Multi-component Regimens (Using of a Manual Toothbrush, a Toothpaste and a Mouthwash)","status":"COMPLETED","sponsor":"Colgate Palmolive","startDate":"2014-06","conditions":"Dental Plaque, Gingivitis","enrollment":179},{"nctId":"NCT01874145","phase":"PHASE3","title":"Safety and Tolerability of Glatiramer Acetate","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-06","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":209},{"nctId":"NCT01317004","phase":"PHASE4","title":"Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":215,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"copolymer 1","genericName":"copolymer 1","companyName":"National Center for Research Resources (NCRR)","companyId":"national-center-for-research-resources-ncrr","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Copolymer 1 is a synthetic polymer that works by inducing an immune response against the myelin basic protein, thereby reducing inflammation in the central nervous system. Used for Relapsing-remitting multiple sclerosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}